WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has initiated a discovery program for a measles monoclonal antibody (mAb). Multiple healthcare ...

Outlines broad discovery and development efforts targeting synthetic lethality and DNA-damage repair mechanisms, including PRMT5-MTA, SGR-3515 and SGR-2921 programs NEW YORK--(BUSINESS ...

Invivyd, Inc. has launched a discovery program for a monoclonal antibody (mAb) targeting measles, following requests from healthcare providers for a treatment option for active infections and ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to ...

Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an equity investment in Aitia as part of the ...